Cholangiocarcinoma
(Bile Duct Cancer)

Approximately 8,000 individuals in the United States are diagnosed with cholangiocarcinoma (CCA) each year.6 About 10-16% of iCCA patients have FGFR2 fusions or rearrangements.7-9

right arrow

The PROOF Trial of infigratinib* for the treatment of advanced/metastatic inoperable cholangiocarcinoma with FGFR2 fusions is currently enrolling.


Learn more about the Phase 3, First-line PROOF Trial for Cholangiocarcinoma


  1. Infigratinib is not currently FDA approved for this indication in the U.S. and is not approved for use by any other health authority.
Cholangiocarcinoma Foundation Logo

Our community

QED has partnered with the Cholangiocarcinoma Foundation, whose mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (bile duct cancer). This partnership allows QED to collaborate with leading disease experts in the Cholangiocarcinoma Foundation network.

The Cholangiocarcinoma Foundation strongly encourages early molecular biomarker testing for patients with cholangiocarcinoma. When it comes to effective treatment options, mutations matter.


Learn why mutations matter

Urothelial Carcinoma (Urinary Tract and Bladder Cancer)

FGFR3 genetic alterations are an oncogenic driver in some urothelial carcinomas. FGFR3 genetic alterations are found in:

  • 21% of advanced urothelial bladder carcinomas10,11
  • Up to 74% of all stages of upper tract urothelial carcinomas (UTUCs)12
    • Estimates suggest that 21%-38% of invasive (≥T2) UTUC harbor FGFR3 genetic alterations11-15

FGFR=fibroblast growth factor receptor.

PROOF 302 is a Phase 3, multicenter, double-blind, randomized, placebo-controlled trial of infigratinib* for the adjuvant treatment of subjects with invasive urothelial carcinoma with FGFR3 genetic alterations. This trial is currently open and enrolling.

Learn more about Phase 3 PROOF 302 Trial for invasive urothelial carcinoma, which is currently enrolling


  1. Infigratinib is not currently FDA approved for this indication in the U.S. and is not approved for use by any other health authority.

References

  1. Touat M et al. Clin Cancer Res. 2015;21(12):2684-2694.
  2. Turner N et al. Nat Rev Cancer. 2010;10:116-129.
  3. Katoh M. Nat Rev Clin Oncol. 2019;16:105-122.
  4. Babina IS et al. Nat Rev Cancer. 2017;17:318-332.
  5. TRUSELTIQ Prescribing Information. Brisbane, CA: QED Therapeutics, Inc.; [Month] 2021.
  6. American Cancer Society. https://www.cancer.org/cancer/bile-duct-cancer/about/key-statistics. Accessed March 27, 2021.
  7. Lamarca A et al. J Clin Med. 2020;9(9):2854.
  8. Arai Y et al. Hepatology. 2014;59(4):1427-1434.
  9. Kongpetch S et al. JCO Global Oncol. 2020;6:628-638.
  1. Ross JS et al. Cancer. 2016;122(5):702-711.
  2. Sfakianos JP et al. Eur Urol. 2015;68(6):970-977.
  3. Moss TJ et al. Eur Urol. 2017;72(4):641-649.
  4. Bagrodia A et al. J Urol. 2016;195(6):1684-1689.
  5. Bagrodia A et al. Eur Urol Focus. 2019;5(3):365-368.
  6. Audenet F et al. Clin Cancer Res. 2019;25(3):967-976.
  7. Komla-Ebri D et al. J Clin Invest. 2016;126(5):1871-1884.
  8. National Institutes of Health. https://ghr.nlm.nih.gov/condition/achondroplasia. Accessed April 1, 2021.
  9. Legare JM et al. https://www.ncbi.nlm.nih.gov/books/NBK1152/. Accessed April 1, 2021.

Contact Us

8000 Marina Blvd, Suite 400, Brisbane, CA 94005

1-877-280-5655

For additional information, reach out to info@qedtx.com